Research progress of AIDS vaccine

Liu Yong,Shao Yiming
DOI: https://doi.org/10.3969/j.issn.1007-8134.2009.06.003
2009-01-01
Abstract:AIDS vaccine research has encountered obstacles and setbacks. After the failure of first generation gp120 based protein vaccine candidate AIDSVAX in the phase Ⅲ clinical trials in Europe,America and Thailand,Merck's adenovirus vector-based second generation T cell vaccine did not provide protective immunity,but showed higher risk of HIV infection in particular subgroups of vaccinees. Despite all these defeats,scientists have been putting forward novel vaccine strategies such as immunogen screening and structure-based immunogen design. Subsequently after 25 years of research efforts,the AIDSVAX B/E prime-ALVAC-HIV boost regimen has shown partial protection in the phaseⅢ trials concluded in Thailand. The confidence for a successful AIDS vaccine has regained.
What problem does this paper attempt to address?